趋实医疗设备 2025年季度报告

FORM10-Q (MARK ONE) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDEDSEPTEMBER 30,2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER001-36159 STEREOTAXIS, INC.(Exact name of the Registrant as Specified in its Charter) 710 North Tucker Boulevard,Suite 110St. Louis,MO63101(Address of Principal Executive Offices including Zip Code) (314)678-6100(Registrant’s Telephone Number, Including Area Code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T “See 232.405 of this Chapter” during the preceding 12 months (or for such shorter period that the registrant wasrequired to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Accelerated Filer☐Non-accelerated filer☒Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes☐No☒ The number of outstanding shares of the registrant’s common stock on October 31, 2025, was93,324,763. STEREOTAXIS, INC.INDEX TO FORM 10-Q Part I Financial Information Item 1.Consolidated Financial Statements (unaudited)3-7Consolidated Balance Sheets3Consolidated Statements of Operations4Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity5-6Consolidated Statements of Cash Flows7Notes to Financial Statements8-23Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations24-31Item 3.[Reserved]31Item 4.Controls and Procedures31 Part II Other Information Item 1.Legal Proceedings32Item 1A.Risk Factors32Item 2.Unregistered Sales of Equity Securities and Use of Proceeds32Item 3.Defaults upon Senior Securities32Item 4.[Reserved]32Item 5.Other Information32Item 6.Exhibits32 ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS STEREOTAXIS, INC.CONSOLIDATED BALANCE SHEETS STEREOTAXIS, INC.CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY(Unaudited) Three Months Ended September 30, 2024 STEREOTAXIS, INC.CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY(Unaudited) Nine Months Ended September 30, 2024 STEREOTAXIS, INC.CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited) STEREOTAXIS, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS(Unaudited) Notes to Consolidated Financial Statements In this report, “Stereotaxis”, the “Company”, “Registrant”, “we”, “us”, and “our” refer to Stereotaxis, Inc. and its wholly ownedsubsidiaries. GenesisX RMN®, Genesis RMN®, Niobe®, Navigant®, Synchrony™, SynX™, Odyssey®, Odyssey Cinema™, MAGiC™,EMAGIN™, Map-iT™, QuikCAS™,Cardiodrive®, Vdrive®, Vdrive Duo™, V-CAS™, V-Loop™, V-Sono™, and NuVizion™ are trademarksof Stereotaxis, Inc. All other trademarks that appear in this report are the property of their respective owners. 1.Description of Business Stereotaxis designs, manufactures and markets robotic systems, instruments and information systems for the interventional laboratory. Ourproprietary robotic technology, Robotic Magnetic Navigation, fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. Direct control of the tip of an interventionaldevice, in contrast to all manual hand-held devices that are controlled from their handle, can improve the precision, stability, reach and safety ofthese devices during procedures. Our primary clinical focus has been electrophysiology, specifically cardiac ablation procedures for the treatment of arrhythmias. Cardiacablation has become a well-accepted therapy for arrhythmias and a multi-billion-dollar medical device market with expectations for substantiallong-term growth. We have shared our aspirations and a product strategy to expand the clinical focus of